Dexilant approved to treat heartburn in younger patients
The Food and Drug Administration has approved Dexilant (dexlansoprazole) for gastroesophageal reflux disease patients aged 12-17 years, according to a press release from Takeda Pharmaceuticals.
FDA...
Source: Pediatric News - Category: Journals (General) Source Type: news
More News: Acid Reflux | Dexilant | Food and Drug Administration (FDA) | Gastroenterology | Gastroesophageal Reflux Disease | General Medicine | GERD | Heartburn | Pediatrics